文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

巨噬细胞极化作为老年人脓毒症相关认知障碍的潜在驱动因素和治疗靶点

Macrophages Polarization as a Potential Driver and a Therapeutic Target for Sepsis-induced Cognitive Impairment in Older Adults.
PubMed 文献 · Shock · 2025-09-24
一句话结论脓毒症通过驱动巨噬细胞向促炎M1表型极化并阻碍向M2表型转化,可能介导老年人短期谵妄和长期认知障碍,巨噬细胞极化是潜在治疗靶点。

本文为综述,聚焦老年人脓毒症存活者持续存在的神经认知并发症(记忆、注意力、执行功能损害,严重者表现为脓毒症相关谵妄或进展为长期认知障碍和痴呆)。核心机制为持续性神经炎症桥接外周免疫激活与中枢神经系统损伤,巨噬细胞(包括循环单核细胞和脑内小胶质细胞)是关键调控者。脓毒症时巨噬细胞向促炎M1表型极化,释放细胞因子和活性氧加重血脑屏障破坏和神经元损伤;向M2表型转化受损则阻碍炎症消退和组织修复。这种交互是双向的,活化小胶质细胞的神经炎症信号可影响外周巨噬细胞行为,形成自我强化的炎症环路,可能延长中枢神经系统损伤。

要点

  • 脓毒症时巨噬细胞向促炎M1表型极化,释放细胞因子和活性氧,加重血脑屏障破坏和神经元损伤。
  • 巨噬细胞向M2表型转化受损,阻碍炎症消退和组织修复,与持续神经炎症相关。
  • 活化小胶质细胞的神经炎症信号可影响外周巨噬细胞行为,形成自我强化的炎症环路,可能延长中枢神经系统损伤。
  • 老年人因可能存在预先存在的免疫脆弱性和不同的基线认知状态,治疗靶向面临独特挑战。
  • 理解全身和神经炎症通路如何通过巨噬细胞信号汇聚,可能揭示减轻脓毒症存活者长期神经并发症的新治疗靶点。

适用人群与场景

  • 老年人脓毒症存活者,关注急性期后持续神经认知并发症(记忆、注意力、执行功能损害)的人群。
  • 严重者可表现为脓毒症相关谵妄或进展为长期认知障碍和痴呆。

研究设计与关键结果

  • 综述指出,脓毒症改变巨噬细胞亚群的丰度和极化,在急性期可能表现为脓毒症相关谵妄(SAD),长期则持续免疫失调和神经炎症可能 contribute to 持续认知缺陷,包括记忆丧失和执行功能障碍。
  • 脓毒症期间炎症条件常驱动巨噬细胞向促炎M1表型极化,导致细胞因子和活性氧释放,加剧血脑屏障破坏和神经元损伤。
  • 向M2表型转化受损阻碍炎症消退和组织修复。
  • 小胶质细胞与外周巨噬细胞的交互是双向的,形成自我强化的炎症环路,可能延长中枢神经系统损伤。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,理解全身和神经炎症通路如何通过巨噬细胞信号汇聚,可能揭示减轻脓毒症存活者长期神经并发症的新治疗靶点。
  • 作者指出,老年人因可能存在预先存在的免疫脆弱性和不同的基线认知状态,治疗靶向面临独特挑战。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Sepsis, a dysregulated host response to infection, remains a growing global health concern, particularly in older adults. While much attention focuses on acute survival, an increasing number of sepsis survivors experience persistent neurological complications, including impairments in memory, attention, and executive function. In severe cases, these may manifest as sepsis-associated delirium or progress to long-term cognitive impairment and dementia. The mechanisms driving these outcomes are complex and incompletely understood, partly due to limited baseline cognitive data and significant variability among older adults. A central feature of sepsis-induced brain dysfunction is sustained neuroinflammation, which bridges peripheral immune activation and central nervous system injury. Mounting evidence implicates macrophages, including circulating monocytes and brain-resident microglia, as key regulators of this neuroimmune axis. Inflammatory conditions during sepsis often drive macrophage polarization toward a pro-inflammatory M1 phenotype, leading to the release of cytokines and reactive oxygen species that exacerbate blood-brain barrier disruption and neuronal injury. Conversely, impaired transition to the M2 phenotype hinders inflammation resolution and tissue repair. Critically, this interaction is bidirectional, where neuroinflammatory signals from activated microglia can influence peripheral macrophage behavior, creating a self-reinforcing inflammatory loop that may prolong central nervous system damage. This process is especially concerning in older adults who may have preexisting immune vulnerabilities and varying baseline cognitive status, which presents unique challenges for therapeutic targeting. This review highlights the central and dynamic role of macrophage polarization in sepsis-associated cognitive decline. Understanding how systemic and neuroinflammatory pathways converge through macrophage signaling may reveal new therapeutic targets to mitigate long-term neurological complications in sepsis survivors. Graphical abstract-Sepsis alters the abundance and polarization of macrophage subpopulations, contributing to both short- and long-term cognitive impairment. In the acute phase, these changes may manifest as sepsis-associated delirium (SAD), while in the long term, sustained immune dysregulation and neuroinflammation may contribute to persistent cognitive deficits, including memory loss and executive dysfunction.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Zeidan RS, Reinhard S, Sykes S, et al. Macrophages Polarization as a Potential Driver and a Therapeutic Target for Sepsis-induced Cognitive Impairment in Older Adults. Shock. 2025. PMID: 41115112. doi:10.1097/SHK.0000000000002723

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。